2257.HK Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (28 birž. 2024 @ 09:18):
Our systems believe the stock currently is undervalued by 0.05% compare to its pairs and should correct upwards.

Stats
Dzisiejszy wolumen	3.36M
Średni wolumen	3.49M
Kapitalizacja rynkowa	386.49M
EPS	HKD0 ( Q3 \| 2023-09-30 )
Last Dividend	HKD0 ( N/A )
Next Dividend	HKD0 ( N/A )
P/E	-0.550 (Sector) 14.27 (Industry) 6.31
ATR14	HKD0.0110 (0.25%)

0690.HK -1.54%

1061.HK -0.82%

1167.HK 1.32%

1177.HK -0.37%

1228.HK 0.00%

1477.HK 0.30%

1521.HK -1.22%

1530.HK -1.12%

1548.HK -1.18%

1672.HK -3.61%

1873.HK 0.00%

1875.HK -0.91%

1877.HK -2.21%

1952.HK -1.89%

2096.HK -1.56%

2126.HK -3.50%

2137.HK -1.96%

2142.HK -2.21%

2157.HK -3.53%

2162.HK -3.88%

2171.HK -2.24%

2179.HK -3.00%

2197.HK 1.45%

2256.HK 3.68%

2257.HK 3.04%

2616.HK 2.70%

2696.HK -1.09%

3759.HK -1.16%

6160.HK 0.76%

6600.HK 0.86%

6622.HK 0.71%

6628.HK 2.00%

6821.HK 0.51%

6826.HK 2.24%

6978.HK 2.88%

6996.HK 0.00%

6998.HK -1.75%

9688.HK -0.45%

9926.HK -3.23%

9939.HK -4.59%

9966.HK -1.24%

9969.HK 4.52%

9995.HK -4.86%

Korelacja (AI algo v.1.1b): Undervalued: 0.05% HKD4.41 paired level. (Algorytm śledzi zmiany najbardziej skorelowanych akcji w czasie rzeczywistym i natychmiast aktualizuje)

Wolumen Korelacja

Długi: 0.15 (neutral)

Krótki: -0.55 (weak negative)

Signal:(45.302) Neutral

Sirnaomics Ltd. Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Sirnaomics Ltd. Korelacja - Waluta/Towar

0.11
( neutral )

0.05
( neutral )

0.00
( neutral )

0.36
( neutral )

0.57
( weak )

0.65
( weak )

Sirnaomics Ltd. Finanse

Annual	2023
Przychody:	HKD397 000
Zysk brutto:	HKD397 000 (100.00 %)
EPS:	HKD-1.030

FY	2023
Przychody:	HKD397 000
Zysk brutto:	HKD397 000 (100.00 %)
EPS:	HKD-1.030

FY	2022
Przychody:	HKD0
Zysk brutto:	HKD0 (0.00 %)
EPS:	HKD-1.160

Financial Reports:

No articles found.

Sirnaomics Ltd. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Sirnaomics Ltd.

Sirnaomics Ltd., an RNA therapeutics biopharmaceutical company, focuses on the discovery and development of product candidates for indications with medical needs in the United Sates and the People's Republic of China. Its lead product candidates include STP705 for the treatment cutaneous squamous cell carcinoma in situ; basal cell carcinoma; cholangiocarcinoma, hepatocellular carcinoma, liver metastases, etc.; keloid scarless healing, hypertrophic scarring, and fat sculpting. The company's lead product candidates also comprise STP707 to treat cholangiocarcinoma, hepatocellular carcinoma, liver metastases, etc.; metastatic cutaneous squamous cell carcinoma; non-small cell lung cancer; liver fibrosis; and lung fibrosis. It also develops STP355 for the treatment of pan cancer; STP369 to treat head and neck/bladder cancer; STP779 for the treatment of liver/lung/pancreatic cancer; STP902 to treat breast cancer; STP702 for the treatment of influenza; STP908 to treat COVID-19; RIM730 COVID-19 vaccine; STP909 for the treatment of HPV/cervical cancer; and STP122G for thrombotic disorders. In addition, the company is developing STP125G to treat hypertriglyceridemia; STP144G for the treatment of complement-mediated diseases; STP133G for cardiometabolic; and STP155G for the treatment hepatitis B virus. Sirnaomics Ltd. was founded in 2007 and is headquartered in Gaithersburg, Maryland.